Physician profile
Glen Lilly
NPI 1275935934
$1,953.51
in general payments reported to CMS, 2019-2025
26 companies · $384 in 2025
The $384 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $308 · 2023: $595 · 2024: $666 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $400.47 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $275.09 | 2022-2025 | |
| Lilly USA, LLC | $215.71 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $148.22 | 2022-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $99.51 | 2022-2024 | |
| Exact Sciences Corporation | $82.85 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $82.37 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $80.88 | 2023-2025 | Voquezna |
| Amgen INC. | $75.11 | 2023-2025 | Otezla, Repatha, Krystexxa |
| Corcept Therapeutics | $54.50 | 2025 | Korlym |
| Pfizer INC. | $53.44 | 2022-2024 | |
| Averitas Pharma INC. | $50.15 | 2023-2024 | Qutenza |
| Janssen Biotech, INC. | $47.07 | 2025 | Tremfya |
| Recordati_rare_diseases_inc. | $40.97 | 2024-2025 | Isturisa, Signifor Lar |
| Glaxosmithkline, LLC. | $38.54 | 2023-2024 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $35.72 | 2023 | Verquvo, Belsomra, Steglatro |
| Idorsia Pharmaceuticals US INC | $26.08 | 2023 | Quviviq |
| Alnylam Pharmaceuticals INC. | $21.68 | 2024 | Onpattro |
| Alexion Pharmaceuticals, INC. | $18.99 | 2025 | Strensiq |
| Ucb, INC. | $18.03 | 2024 | Bimzelx |
| Boston Scientific Corporation | $17.21 | 2024 | Watchman Access System |
| Janssen Pharmaceuticals, INC | $15.37 | 2022 | |
| Antares Pharma, INC. | $15.04 | 2022 | |
| Nevro Corp. | $14.00 | 2023 | Senza |
| Currax Pharmaceuticals LLC | $13.41 | 2024 | Contrave |
| Intra-Sana Laboratories | $13.10 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Lilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.